Patents by Inventor Binh Thanh Vu
Binh Thanh Vu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9371280Abstract: There are provided compounds of the formula wherein X, Y, Z, R1, R2 and R3 are as described herein and enantiomers and pharmaceutically acceptable salts and esters thereof. The compounds are useful as anticancer agents.Type: GrantFiled: May 29, 2013Date of Patent: June 21, 2016Assignee: HOFFMANN-LA ROCHE INC.Inventors: David Joseph Bartkovitz, Xin-Jie Chu, George Kenneth Ehrlich, Jin-Jun Liu, Hanspeter Michel, Binh Thanh Vu, Chunlin Zhao
-
Patent number: 8993614Abstract: There are provided compounds of the formula wherein X, Y, Z, R1, R2, R3 and R4 are as described herein and enantiomers and pharmaceutically acceptable salts and esters thereof. The compounds are useful as anticancer agents.Type: GrantFiled: March 5, 2013Date of Patent: March 31, 2015Assignee: F. Hoffmann-La Roche AGInventors: David Joseph Bartkovitz, Xin-Jie Chu, Binh Thanh Vu, Chunlin Zhao, Daniel Fishlock
-
Publication number: 20140148443Abstract: Disclosed are compounds of Formula I or pharmaceutically acceptable salts thereof, wherein X1, X2, X3, R1, R2 and R3 are as described in this application, and methods of using the compounds in the treatment of cancer.Type: ApplicationFiled: November 20, 2013Publication date: May 29, 2014Applicant: Hoffmann-La Roche Inc.Inventors: Xin-Jie Chu, Allen John Lovey, Binh Thanh Vu, Chunlin Zhao
-
Publication number: 20130324531Abstract: There are provided compounds of the formula wherein X, Y, Z, R1, R2 and R3 are as described herein and enantiomers and pharmaceutically acceptable salts and esters thereof. The compounds are useful as anticancer agents.Type: ApplicationFiled: May 29, 2013Publication date: December 5, 2013Applicant: Hoffmann-La Roche Inc.Inventors: David Joseph Bartkovitz, Xin-Jie Chu, George Kenneth Ehrlich, Jin-Jun Liu, Hanspeter Michel, Binh Thanh Vu, Chunlin Zhao
-
Publication number: 20130244958Abstract: There are provided compounds of the formula wherein X, Y, Z, R1, R2, R3 and R4 are as described herein and enantiomers and pharmaceutically acceptable salts and esters thereof. The compounds are useful as anticancer agents.Type: ApplicationFiled: March 5, 2013Publication date: September 19, 2013Applicant: Hoffmann-La Roche Inc.Inventors: David Joseph Bartkovitz, Xin-Jie Chu, Binh Thanh Vu, Chunlin Zhao, Daniel Fishlock
-
Patent number: 8513239Abstract: There are provided compounds of the formula or the pharmaceutically acceptable salts thereof, wherein X, Y, Z, V1, V2, R1, R2, R3, R4 and R5 are herein described. These compounds are useful as anticancer agents.Type: GrantFiled: October 9, 2008Date of Patent: August 20, 2013Assignee: Hoffmann-La Roche Inc.Inventors: David Joseph Bartkovitz, Jianping Cai, Xin-Jie Chu, Hongju Li, Allen John Lovey, Binh Thanh Vu, Chunlin Zhao
-
Patent number: 7964724Abstract: and the pharmaceutically acceptable salts and esters thereof, wherein X1, X2, X3, Y1, Y2 and R are described herein inhibit the interaction of MDM2 protein with a p53-like peptide and hence have anti proliferative activity.Type: GrantFiled: May 13, 2005Date of Patent: June 21, 2011Assignee: Hoffmann-La Roche Inc.Inventors: Nader Fotouhi, Gregory Jay Haley, Klaus B. Simonsen, Binh Thanh Vu, Stephen Evan Webber
-
Patent number: 7893278Abstract: The present invention relates to compounds of the formula and the pharmaceutically acceptable salts and esters thereof, a process for their manufacture, medicaments containing them as well as the use of these compounds as pharmaceutically active agents. The compounds show antiproliferative activity and may be especially useful for the treatment of cancer.Type: GrantFiled: June 2, 2005Date of Patent: February 22, 2011Assignee: Hoffman-La Roche Inc.Inventors: Gregory Jay Haley, Norman Kong, Emily Aijun Liu, Binh Thanh Vu
-
Patent number: 7851626Abstract: There is provided a compound of formula I and the pharmaceutically acceptable salts and esters thereof wherein X1, X2, R1, R2, R3, R4, R5 and R6 are herein described. The compounds exhibit activity as anticancer agents.Type: GrantFiled: November 27, 2006Date of Patent: December 14, 2010Assignee: Hoffmann-La Roche Inc.Inventors: Qingjie Ding, Bradford James Graves, Norman Kong, Jin-Jun Liu, Allen John Lovey, Giacomo Pizzolato, John Lawson Roberts, Sung-Sau So, Binh Thanh Vu, Peter Michael Wovkulich
-
Patent number: 7705007Abstract: There are provided compounds of the formula I wherein R, V1, V2 and Ring A are described herein. The compounds exhibit anticancer activity.Type: GrantFiled: January 17, 2007Date of Patent: April 27, 2010Assignee: Hoffmann-La Roche Inc.Inventors: Nader Fotouhi, Gregory Jay Haley, Klaus B. Simonsen, Binh Thanh Vu, Stephen Evan Webber
-
Patent number: 7625895Abstract: and the pharmaceutically acceptable salts and esters thereof, X, R1, R2, Y1 and Y2 are described herein inhibit the interaction of MDM2 protein with a p53-like peptide and hence have anti proliferative activity.Type: GrantFiled: March 18, 2008Date of Patent: December 1, 2009Assignee: Hoffmann-Le Roche Inc.Inventors: Romyr Dominique, Robert Alan Goodnow, Jr., Qi Qiao, Binh Thanh Vu
-
Patent number: 7615634Abstract: Novel intermediate compounds are disclosed. These compounds are useful in the synthesis of 4-aminopyrimidine-5-one derivatives that inhibit cyclin-dependent kinases, in particular cyclin-dependent kinase 4 (Cdk4). The 4-aminopyrimidine-5-one derivatives and their pharmaceutically acceptable salts have antiproliferative activity and are useful in the treatment or control of cancer, in particular solid tumors.Type: GrantFiled: June 20, 2006Date of Patent: November 10, 2009Assignee: Hoffmann-La Roche Inc.Inventors: David Joseph Bartkovitz, Xin-Jie Chu, Qingjie Ding, Nan Jiang, Allen John Lovey, John Anthony Moliterni, John Guilfoyle Mullin, Jr., Binh Thanh Vu, Peter Michael Wovkulich
-
Patent number: 7579368Abstract: There are presented compounds of the formula or pharmaceutically acceptable salts thereof, wherein Y1, Y2, X1, X2, X3 and R are as described in this application. These compounds are believed to inhibit MDM2-p53 interaction and as such the compounds will have anti-hyperproliferative cellular activity.Type: GrantFiled: March 13, 2006Date of Patent: August 25, 2009Assignee: Hoffman-La Roche Inc.Inventors: Nader Fotouhi, Gregory Jay Haley, Klaus B. Simonsen, Binh Thanh Vu, Stephen Evan Webber
-
Publication number: 20090143364Abstract: and the pharmaceutically acceptable salts and esters thereof, wherein X1, X2, X3, Y1, Y2 and R are described herein inhibit the interaction of MDM2 protein with a p53-like peptide and hence have anti proliferative activity.Type: ApplicationFiled: February 5, 2009Publication date: June 4, 2009Inventors: Nader Fotouhi, Gregory Jay Haley, Klaus B. Simonsen, Binh Thanh Vu, Stephen Evan Webber
-
Publication number: 20090111789Abstract: There are provided compounds of the formula or the pharmaceutically acceptable salts thereof, wherein X, Y, Z, V1, V2, R1, R2, R3, R4 and R5 are herein described. These compounds are useful as anticancer agents.Type: ApplicationFiled: October 9, 2008Publication date: April 30, 2009Inventors: David Joseph Bartkovitz, Jianping Cai, Xin-Jie Chu, Hongju Li, Allen John Lovey, Binh Thanh Vu, Chunlin Zhao
-
Publication number: 20080255119Abstract: and the pharmaceutically acceptable salts and esters thereof X, R1, R2, Y1 and Y2 are described herein inhibit the interaction of MDM2 protein with a p53-like peptide and hence have anti proliferative activity.Type: ApplicationFiled: March 18, 2008Publication date: October 16, 2008Inventors: Romyr Dominique, Robert Alan Goodnow, Qi Qiao, Binh Thanh Vu
-
Patent number: 7425638Abstract: The present invention provides compounds according to formula I having the designations provided herein, and pharmaceutically acceptable salts and esters thereof. These compounds inhibit the interaction of MDM2 protein with a p53-like peptide and have antiproliferative activity.Type: GrantFiled: June 14, 2004Date of Patent: September 16, 2008Assignee: Hoffmann-La Roche Inc.Inventors: Gregory Jay Haley, Norman Kong, Emily Aijun Liu, Klaus B. Simonsen, Binh Thanh Vu, Stephen Evan Webber
-
Patent number: 7157455Abstract: Novel 4-aminopyrimidine-5-one derivatives are disclosed. These compounds inhibit cyclin-dependent kinases, in particular cyclin-dependent kinase 4 (Cdk4). These compounds and their pharmaceutically acceptable salts and esters have antiproliferative activity and are useful in the treatment or control of cancer, in particular solid tumors. This invention is also directed to pharmaceutical compositions containing such compounds and to methods of treating or controlling cancer, most particularly the treatment or control of breast, lung, colon and prostate tumors. Also disclosed are intermediates useful in the preparation of these novel 4-aminopyrimidine-5-one derivatives.Type: GrantFiled: February 2, 2004Date of Patent: January 2, 2007Assignee: Hoffmann-La Roche Inc.Inventors: David Joseph Bartkovitz, Xin-Jie Chu, Qingjie Ding, Nan Jiang, Allen John Lovey, John Anthony Moliterni, John Guilfoyle Mullin, Jr., Binh Thanh Vu, Peter Michael Wovkulich
-
Patent number: 7132421Abstract: The present invention provides compounds according to formula I and pharmaceutically acceptable salts and esters thereof, having the designations provided herein and which inhibit the interaction of MDM2 protein with a p53-like peptide and have antiproliferative activityType: GrantFiled: June 15, 2004Date of Patent: November 7, 2006Assignee: Hoffmann-La Roche Inc.Inventors: Nader Fotouhi, Emily Aijun Liu, Binh Thanh Vu
-
Publication number: 20040259884Abstract: The present invention provides compounds according to formula I 1Type: ApplicationFiled: June 14, 2004Publication date: December 23, 2004Inventors: Gregory Jay Haley, Norman Kong, Emily Aijun Liu, Klaus B. Simonsen, Binh Thanh Vu, Stephen Evan Webber